Carolina Johansson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carolina Johansson has a total of 170 co-authors. Here are the top co-authors by number of shared publications:
- Martin Schalling
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
11 shared publications - Sandra Ceccatelli
Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
9 shared publications - Rolf Adolfsson
Umeå University
7 shared publications - Timo Partonen
Department of Healthcare and Social Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland
7 shared publications - Siegfried Kasper
Medizinische Universität Wien
5 shared publications Luigi Manzo
Toxicology Division, IRCCS Salvatore Maugeri Foundation and University of Pavia, Via Palestro 26, 27100 Pavia, Italy
4 shared publications
Latest Publications
- Open Access
- 15 November 2014
- Published by Wiley in International Journal of Cancer
- Vol. 136 (12) , 2844-2853
MGMT promoter methylation is associated with temozolomide response and prolonged progression‐free survival in disseminated cutaneous melanoma
To investigate the predictive and prognostic value of O6‐methylguanine DNA methyltransferase (MGMT) inactivation by analyses of promoter methylation in pretreatment tumor biopsies from patients with cutaneous melanoma treated with dacarbazine (DTIC) or temozolomide (TMZ) were performed. The patient cohorts consisted of Belgian and Swedish disseminated melanoma patients. Patients were subdivided into those receiving single‐agent treatment with DTIC/TMZ (cohort S, n = 74) and those treated with combination chemotherapy including DTIC/TMZ (cohort C, n = 79). Median follow‐up was 248 and 336 days for cohort S and cohort C, respectively. MGMT promoter methylation was assessed by three methods. The methylation‐related transcriptional silencing of MGMT mRNA expression was assessed by real‐time RT‐PCR. Response to chemotherapy and progression‐free survival (PFS) and overall survival were correlated to MGMT promoter methylation status. MGMT promoter methylation was detected in tumor biopsies from 21.5 % of the patients. MGMT mRNA was found to be significantly lower in tumors positive for MGMT promoter methylation compared to tumors without methylation in both treatment cohorts (p < 0.005). DTIC/TMZ therapy response rate was found to be significantly associated with MGMT promoter methylation in cohort S (p = 0.0005), but did not reach significance in cohort C (p = 0.16). Significantly longer PFS was observed among patients with MGMT promoter‐methylated tumors (p = 0.002). Multivariate Cox regression analysis identified presence of MGMT promoter methylation as an independent variable associated with longer PFS. Together, this implies that MGMT promoter methylation is associated with response to single‐agent DTIC/TMZ and longer PFS in disseminated cutaneous melanoma.
- 15 November 2014
- Published by Wiley in International Journal of Cancer
- Vol. 136 (12) , 2844-2853
Open AccessMGMT promoter methylation is associated with temozolomide response and prolonged progression‐free survival in disseminated cutaneous melanoma
To investigate the predictive and prognostic value of O6‐methylguanine DNA methyltransferase (MGMT) inactivation by analyses of promoter methylation in pretreatment tumor biopsies from patients with cutaneous melanoma treated with dacarbazine (DTIC) or temozolomide (TMZ) were performed. The patient cohorts consisted of Belgian and Swedish disseminated melanoma patients. Patients were subdivided into those receiving single‐agent treatment with DTIC/TMZ (cohort S, n = 74) and those treated with combination chemotherapy including DTIC/TMZ (cohort C, n = 79). Median follow‐up was 248 and 336 days for cohort S and cohort C, respectively. MGMT promoter methylation was assessed by three methods. The methylation‐related transcriptional silencing of MGMT mRNA expression was assessed by real‐time RT‐PCR. Response to chemotherapy and progression‐free survival (PFS) and overall survival were correlated to MGMT promoter methylation status. MGMT promoter methylation was detected in tumor biopsies from 21.5 % of the patients. MGMT mRNA was found to be significantly lower in tumors positive for MGMT promoter methylation compared to tumors without methylation in both treatment cohorts (p < 0.005). DTIC/TMZ therapy response rate was found to be significantly associated with MGMT promoter methylation in cohort S (p = 0.0005), but did not reach significance in cohort C (p = 0.16). Significantly longer PFS was observed among patients with MGMT promoter‐methylated tumors (p = 0.002). Multivariate Cox regression analysis identified presence of MGMT promoter methylation as an independent variable associated with longer PFS. Together, this implies that MGMT promoter methylation is associated with response to single‐agent DTIC/TMZ and longer PFS in disseminated cutaneous melanoma.
- 1 May 2014
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 142 (2) , 176-182
BRAF inhibitors in cancer therapy
- 1 May 2014
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 142 (2) , 176-182
BRAF inhibitors in cancer therapy
- Open Access
- 10 April 2014
- Published by Springer Nature in British Journal of Cancer
- Vol. 110 (10) , 2489-2495
Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance
Disseminated cutaneous malignant melanoma (CMM) is commonly unresponsive to standard chemotherapies, and there are as yet no predictive markers of therapy response. In the present study we collected fresh-frozen pretreatment lymph-node metastasis samples (n=14) from melanoma patients with differential response to dacarbazine (DTIC) or temozolomide (TMZ) chemotherapy, to identify proteins with an impact on treatment response. We performed quantitative protein profiling using tandem mass spectrometry and compared the proteome differences between responders (R) and non-responders (NR), matched for age, gender and histopathological type of CMM. Biological pathway analyses showed several signalling pathways differing between R vs NR, including Rho signalling. Gene expression profiling data was available for a subset of the samples, and the results were compared with the proteomics data. Four proteins with differential expression between R and NR were selected for technical validation by immunoblotting (ISYNA1, F13A1, CSTB and S100A13), and CSTB and S100A13 were further validated on a larger sample set by immunohistochemistry (n=48). The calcium binding protein S100A13 was found to be significantly overexpressed in NR compared with R in all analyses performed. Our results suggest that S100A13 is involved in CMM resistance to DTIC/TMZ.
- 10 April 2014
- Published by Springer Nature in British Journal of Cancer
- Vol. 110 (10) , 2489-2495
Open AccessProteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance
Disseminated cutaneous malignant melanoma (CMM) is commonly unresponsive to standard chemotherapies, and there are as yet no predictive markers of therapy response. In the present study we collected fresh-frozen pretreatment lymph-node metastasis samples (n=14) from melanoma patients with differential response to dacarbazine (DTIC) or temozolomide (TMZ) chemotherapy, to identify proteins with an impact on treatment response. We performed quantitative protein profiling using tandem mass spectrometry and compared the proteome differences between responders (R) and non-responders (NR), matched for age, gender and histopathological type of CMM. Biological pathway analyses showed several signalling pathways differing between R vs NR, including Rho signalling. Gene expression profiling data was available for a subset of the samples, and the results were compared with the proteomics data. Four proteins with differential expression between R and NR were selected for technical validation by immunoblotting (ISYNA1, F13A1, CSTB and S100A13), and CSTB and S100A13 were further validated on a larger sample set by immunohistochemistry (n=48). The calcium binding protein S100A13 was found to be significantly overexpressed in NR compared with R in all analyses performed. Our results suggest that S100A13 is involved in CMM resistance to DTIC/TMZ.
- 1 January 2014
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 134 (1) , 287-290
Somatic BRAF and NRAS Mutations in Familial Melanomas with Known Germline CDKN2A Status: A GenoMEL Study
- 1 January 2014
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 134 (1) , 287-290
Somatic BRAF and NRAS Mutations in Familial Melanomas with Known Germline CDKN2A Status: A GenoMEL Study
- 1 December 2013
- Published by Elsevier in Journal of Dermatological Science
- Vol. 72 (3) , 284-289
KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma
- 1 December 2013
- Published by Elsevier in Journal of Dermatological Science
- Vol. 72 (3) , 284-289
KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma
- 1 October 2013
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 23 (5) , 360-365
Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines
Previous studies in cell lines have suggested a role for melanosomes and related protein trafficking pathways in melanoma drug response. We have investigated the expression of six proteins related to melanosomes and melanogenesis (MITF, GPR143, gp100/PMEL, MLANA, TYRP1, and RAB27A) in pretreatment metastases from melanoma patients (n=52) with different response to dacarbazine/temozolomide. Microphthalmia-associated transcription factor (MITF) and G-protein coupled receptor 143 (GPR143) showed significantly higher expression in nonresponders compared with responders. The premelanosome protein (gp100/PMEL) has been indicated previously in resistance to cisplatin in melanoma cells, but the expression levels of gp100/PMEL showed no association with response to dacarbazine/temozolomide in our clinical material. We also investigated the effects on chemosensitivity of siRNA inhibition of gp100/PMEL in the MNT-1 melanoma cell line. As expected from the study of the tumor material, no effect was detected with respect to response to temozolomide. However, knockdown of gp100/PMEL sensitized the cells to both paclitaxel and cisplatin. Overall, our results suggest that MITF, and several MITF-regulated factors, are associated with resistance to chemotherapy in melanoma and that different MITF targets can be of importance for different drugs. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
- 1 October 2013
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 23 (5) , 360-365
Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines
Previous studies in cell lines have suggested a role for melanosomes and related protein trafficking pathways in melanoma drug response. We have investigated the expression of six proteins related to melanosomes and melanogenesis (MITF, GPR143, gp100/PMEL, MLANA, TYRP1, and RAB27A) in pretreatment metastases from melanoma patients (n=52) with different response to dacarbazine/temozolomide. Microphthalmia-associated transcription factor (MITF) and G-protein coupled receptor 143 (GPR143) showed significantly higher expression in nonresponders compared with responders. The premelanosome protein (gp100/PMEL) has been indicated previously in resistance to cisplatin in melanoma cells, but the expression levels of gp100/PMEL showed no association with response to dacarbazine/temozolomide in our clinical material. We also investigated the effects on chemosensitivity of siRNA inhibition of gp100/PMEL in the MNT-1 melanoma cell line. As expected from the study of the tumor material, no effect was detected with respect to response to temozolomide. However, knockdown of gp100/PMEL sensitized the cells to both paclitaxel and cisplatin. Overall, our results suggest that MITF, and several MITF-regulated factors, are associated with resistance to chemotherapy in melanoma and that different MITF targets can be of importance for different drugs. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
- 19 February 2010
- Published by Springer Nature in Neurotoxicity Research
- Vol. 19 (1) , 183-194
Hippocampal Neurons Exposed to the Environmental Contaminants Methylmercury and Polychlorinated Biphenyls Undergo Cell Death via Parallel Activation of Calpains and Lysosomal Proteases
Methylmercury (MeHg) and polychlorinated biphenyls (PCBs) are widespread environmental pollutants commonly found as contaminants in the same food sources. Even though their neurotoxic effects are established, the mechanisms of action are not fully understood. In the present study, we have used the mouse hippocampal neuronal cell line HT22 to investigate the mechanisms of neuronal death induced by MeHg, PCB 153, and PCB 126, alone or in combination. All chemicals induced cell death with morphological changes compatible with either apoptosis or necrosis. Mitochondrial functions were impaired as shown by the significant decrease in mitochondrial Ca2+ uptake capacity and ATP levels. MeHg, but not the PCBs, induced loss of mitochondrial membrane potential and release of cytochrome c into the cytosol. Also, pre-treatment with the antioxidant MnTBAP was protective only against cell death induced by MeHg. While caspase activation was absent, the Ca2+-dependent proteases calpains were activated after exposure to MeHg or the selected PCBs. Furthermore, lysosomal disruption was observed in the exposed cells. Accordingly, pre-treatment with the calpain specific inhibitor PD150606 and/or the cathepsin D inhibitor Pepstatin protected against the cytotoxicity of MeHg and PCBs, and the protection was significantly enhanced when the two inhibitors were combined. Simultaneous exposures to lower doses of MeHg and PCBs suggested mostly antagonistic interactions. Taken together, these data indicate that MeHg and PCBs induce caspase-independent cell death via parallel activation of calpains and lysosomal proteases, and that in this model oxidative stress does not play a major role in PCB toxicity.
- 19 February 2010
- Published by Springer Nature in Neurotoxicity Research
- Vol. 19 (1) , 183-194
Hippocampal Neurons Exposed to the Environmental Contaminants Methylmercury and Polychlorinated Biphenyls Undergo Cell Death via Parallel Activation of Calpains and Lysosomal Proteases
Methylmercury (MeHg) and polychlorinated biphenyls (PCBs) are widespread environmental pollutants commonly found as contaminants in the same food sources. Even though their neurotoxic effects are established, the mechanisms of action are not fully understood. In the present study, we have used the mouse hippocampal neuronal cell line HT22 to investigate the mechanisms of neuronal death induced by MeHg, PCB 153, and PCB 126, alone or in combination. All chemicals induced cell death with morphological changes compatible with either apoptosis or necrosis. Mitochondrial functions were impaired as shown by the significant decrease in mitochondrial Ca2+ uptake capacity and ATP levels. MeHg, but not the PCBs, induced loss of mitochondrial membrane potential and release of cytochrome c into the cytosol. Also, pre-treatment with the antioxidant MnTBAP was protective only against cell death induced by MeHg. While caspase activation was absent, the Ca2+-dependent proteases calpains were activated after exposure to MeHg or the selected PCBs. Furthermore, lysosomal disruption was observed in the exposed cells. Accordingly, pre-treatment with the calpain specific inhibitor PD150606 and/or the cathepsin D inhibitor Pepstatin protected against the cytotoxicity of MeHg and PCBs, and the protection was significantly enhanced when the two inhibitors were combined. Simultaneous exposures to lower doses of MeHg and PCBs suggested mostly antagonistic interactions. Taken together, these data indicate that MeHg and PCBs induce caspase-independent cell death via parallel activation of calpains and lysosomal proteases, and that in this model oxidative stress does not play a major role in PCB toxicity.
- 31 December 2008
- Published by Elsevier in Medical Hypotheses
- Vol. 70 (1) , 117-121
CREB-regulated diurnal activity patterns are not indicative for depression-like symptoms in mice and men
- 31 December 2008
- Published by Elsevier in Medical Hypotheses
- Vol. 70 (1) , 117-121
CREB-regulated diurnal activity patterns are not indicative for depression-like symptoms in mice and men
- 30 November 2008
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 52 (2) , 197-198
Human developmental neurotoxicity of methylmercury and variables
- 30 November 2008
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 52 (2) , 197-198
Human developmental neurotoxicity of methylmercury and variables
- 1 July 2008
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 51 (2) , 215-229
Neurodevelopmental toxicity of methylmercury: Laboratory animal data and their contribution to human risk assessment
- 1 July 2008
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 51 (2) , 215-229
Neurodevelopmental toxicity of methylmercury: Laboratory animal data and their contribution to human risk assessment